SpyGlass Pharma announced closing $90 million in Series C financing to help support clinical trials of its drug delivery system in the United States.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045
SpyGlass Pharma completes $90 Million Series C financing to advance novel treatments for glaucoma and other chronic ophthalmic diseases
Default sub title
minute read
by Ophthalmology Times | July 10, 2023
